Results 261 to 270 of about 17,182,321 (391)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review. [PDF]

Discov Oncol
Tavakoli S, Samareh-Salavati M, Rahnama MA, Abdolahi S, Hassanzadeh A, Ghazvinian Z, Verdi J, Vousooghi N, Manoochehrabadi S, Chahardouli B, Barkhordar M, Seyhoun I, Ahmadvand M.   +12 more
europepmc   +1 more source

Modern Concepts of Transfusion Therapy: Clinical and Serologic Problems of White Cell Antibodies

, 1978
Chester M. Zmijewski
openalex   +2 more sources

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

An Editorial on the Special Issue "Where Are We Now and Where Is Cell Therapy Headed?" [PDF]

Pharmaceutics
Papait A, Chiodelli P.
europepmc   +1 more source

Combined modality therapy for esophageal squamous cell carcinoma [PDF]

, 1983
R H Franklin, Zwi Steiger, Gangadhar Vaishampayan, Ingida Asfaw, Jerry C. Rosenberg, John J.K. Loh, Judith A. Hoschner, Peter Miller   +7 more
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Nanomaterial assisted natural killer cell therapy. [PDF]

Front Immunol
Yu X, Chen X, Yang Y, Tian Y, Jia J, Tong X.   +5 more
europepmc   +1 more source

VP-16 SALVAGE THERAPY FOR PVB REGIMEN-RESISTANT TESTICULAR GERM CELL TUMORS

, 1987
Haruki Yamazaki, Y Akasaka, Naoya Kondo, Keiichiro Imanaka, Toyohei Machida   +4 more
openalex   +2 more sources

Morphologic and clinical determinants of response to therapy in small cell carcinoma of the lung [PDF]

, 1983
James A. Strauchen, Barbara M. Egbert, Jon C. Kosek, Roy MacKintosh, Dayton S. Misfeldt   +4 more
openalex   +1 more source